Bristol-Myers Squibb to Acquire Celgene
The Scientists Behind the Science
Sharon Cload is vice president of Molecular Discovery Technology at our Cambridge, Mass., site.
Building Toward a Translational Future
Saurabh Saha leads the translational medicine team and returns to the Boston-area to build out the new R&D facility in Cambridge.
Emerging Trends in Immuno-Oncology: A Focus on Resistance
Bristol-Myers Squibb is underwriting a series in partnership with Scientific American, offering expert perspectives on the latest challenges and discoveries in Immuno-Oncology (I-O).
Scientists on the Move
As an R&D footprint expands, several colleagues saw an opportunity to explore new areas of science.
News & Perspectives
A Personal Story About Atrial Fibrillation Detection
Why It’s Important to Understand AFib, Which is a Leading Cause of Stroke.
People
Making a Molecule
For Ryan Moslin, senior immunology researcher at Bristol-Myers Squibb, all great discoveries start from the same place – an idea.
Financial News
2018 Fourth Quarter and Full Year Results
Bristol-Myers Squibb increases fourth quarter revenues 10% to $6 billion.
Looking for Answers?
Quick links to helpful resources.